Breadcrumb

Photo of Najla El Jurdi, M.D.

Najla El Jurdi, M.D.

  • Center for Cancer Research
  • National Cancer Institute
Associate Research Physician
Immune Deficiency Cellular Therapy Program

RESEARCH SUMMARY

Dr. El Jurdi is a hematopoietic cell transplantation and cellular therapy physician focused on clinical and translational investigations to better understand, prevent, and treat Graft-versus-Host Disease (GVHD), with a particular emphasis on chronic GVHD. Her goal is to leverage the expertise of the NIH GVHD multidisciplinary team and intramural program to bring forth novel clinical trials and therapeutic approaches for GVHD. She is strongly committed to improving toxicities, preventing late effects, and improving quality of life for hematopoietic cell transplant patients and survivors.

Areas of Expertise

Hematopoietic Cell Transplantation
Cellular Therapy
Graft Versus Host Disease
Myeloid Malignancies
Survivorship
Late Effects

Publications

Selected Key Publications

Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis

Bolanos-Meade J, Hamadani M, Wu J, Al Malki MM, Martens MJ, Runaas L, Elmariah H, Rezvani AR, Gooptu M, Larkin KT, Shaffer BC, El Jurdi N, Loren AW, Solh M, Hall AC, Alousi AM, Jamy AH, Perales M, Yao JM, Applegate K, Bhatt AS, Kean LS, Efebera YA, Reshef R, Clark W, DiFronzo NL, Leifer E, Horowitz MM, Jones RJ, Holtan SG, for the BMT CTN 1703 Investigators
The New England Journal of Medicine. 388/25: 2338 - 2348, 2023.
Full-Text Article
[ Journal Article ]

Phase II Study of Myeloablative 7-8/8-Matched Allotransplantation with Post-Transplantation Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil

El Jurdi N, Hoover A, O'Leary D, Cao Q, Gupta A, Ebens C, Maakaron JE, Betts BC, Rashidi A, Juckett MB, Lund T, Bachanova V, Macmillan ML, Miller JS, Orchard PJ, Wagner JE, Vercellotti G, Weisdorf DJ, Dusenbery K, Terezakis S, Holtan, SG
Transplantation and Cellular Therapy. 29/9: 576.e1 - 576.e5, 2023.
Full-Text Article
[ Journal Article ]

Pre-transplant and longitudinal changes in faecal microbiome characteristics are associated with subsequent development of chronic graft-versus-host disease

El Jurdi N, Holtan SG, Hoeschen A, Velguth J, Hillmann B, Betts BC, Macmillan ML, Weisdorf DJ, Khoruts A, Rashidi A, Shields-Cutler R
British Journal of Haematology. 203/2: 288-294, 2023.
Full-Text Article
[ Journal Article ]

Steroid-dependent acute GVHD after allogeneic hematopoietic cell transplantation: risk factors and clinical outcomes

El Jurdi N, Rayes A, Macmillan ML, Holtan SG, DeFor TE, Witte J, Arora M, Young J, Weisdorf DJ
Blood Advances. 5/5: 1352-1359, 2021.
Full-Text Article
[ Journal Article ]

High incidence of thromboembolism in patients with chronic GVHD: association with severity of GVHD and donor-recipient ABO blood group

El Jurdi N, Elhusseini H, Beckman J, DeFor TE, Okoev G, Rogosheske J, Lazaryan A, Weiler K, Bachanova V, Betts BC, Blazar BR, Brunstein CG, He F, Holtan SG, Janakiram M, Gangaraju R, Maakaron J, Macmillan ML, Rashidi A, Warlick ED, Bhatia S, Vercellotti G, Weisdorf DJ, Arora M
Blood Cancer Journal. 11/96: 2021.
Full-Text Article
[ Journal Article ]